Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda

被引:11
|
作者
Alhassan, Yussif [1 ]
Twimukye, Adelline [2 ]
Malaba, Thoko [3 ]
Orrell, Catherine [4 ]
Myer, Landon [3 ]
Waitt, Catriona [5 ]
Lamorde, Mohammed [2 ]
Kambugu, Andrew [2 ]
Reynolds, Helen [5 ]
Khoo, Saye [5 ,6 ]
Taegtmeyer, Miriam [1 ,6 ]
机构
[1] Univ Liverpool Liverpool Sch Trop Med, Dept Int Publ Hlth, Community Hlth Syst Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England
[2] Infect Dis Inst, Kampala, Uganda
[3] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa
[4] Desmond Tutu HIV Ctr, Cape Town, South Africa
[5] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England
[6] Royal Liverpool Univ Hosp, Trop Infect Dis Unit, Prescot St, Liverpool, Merseyside, England
关键词
Acceptability; Dolutegravir-based regimen; HIV treatment; Qualitative study; Uganda; South Africa; THERAPY;
D O I
10.1186/s12889-020-09991-w
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundDespite concerns about dolutegravir use in pregnancy, most low- and middle-income countries are accelerating the introduction of dolutegravir-based regimens into national antiretroviral treatment programmes. Questions remain about the acceptability of dolutegravir use in women due to the potential risks in pregnancy. This study from South Africa and Uganda explored community values, preferences and attitudes towards the use of dolutegravir-based regimens in women.MethodsThis study employed a qualitative design involving in-depth interviews and focus group discussion conducted between August 2018 to March 2019. The study was conducted in the months following an announcement of a potential risk for neural tube defects with dolutegravir use among women during conception and the first trimester. Participants included HIV positive pregnant and lactating women and their partners. They were selected purposively from urban poor communities in South Africa and Uganda. Data was analysed thematically in NVivo.ResultsForty-four in-depth interviews and 15 focus group discussions were conducted. Most participants had positive views of dolutegravir-based regimens and perceived it to be more desirable compared with efavirenz-containing regimens. There was widespread concern about use of dolutegravir during pregnancy and among women of childbearing age due to publicity around the possible association with neural tube defects. Acceptability was gendered, with nearly all male participants preferring their female spouses of childbearing potential not to use dolutegravir, while most women not planning pregnancy wanted access to contraception alongside dolutegravir. Community awareness and knowledge of dolutegravir was low and characterised by negative information. Women were concerned about HIV-related stigma and wanted the privacy features of dolutegravir to be strengthened with modification of the pill appearance and disguised packaging.ConclusionsDolutegravir-based regimens were found to be generally acceptable for use in women except during pregnancy. Interest in a dolutegravir-based regimen was linked with its perceived potential to enhance health, privacy and reduce stigma while concerns about neural tube defects were the main potential barrier to dolutegravir uptake in women. In order to optimise the community acceptability and uptake of acceptability-based regimen among women it is critical to strengthen community awareness and understanding of dolutegravir treatment, improve contraception services alongside the introduction of dolutegravir, and engage with male partners.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda
    Yussif Alhassan
    Adelline Twimukye
    Thoko Malaba
    Catherine Orrell
    Landon Myer
    Catriona Waitt
    Mohammed Lamorde
    Andrew Kambugu
    Helen Reynolds
    Saye Khoo
    Miriam Taegtmeyer
    BMC Public Health, 20
  • [2] Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda
    Yussif Alhassan
    Adelline Twimukye
    Thoko Malaba
    Catherine Orrell
    Landon Myer
    Catriona Waitt
    Mohammed Lamorde
    Andrew Kambugu
    Helen Reynolds
    Saye Khoo
    Miriam Taegtmeyer
    BMC Health Services Research, 20
  • [3] Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda
    Alhassan, Yussif
    Twimukye, Adelline
    Malaba, Thoko
    Orrell, Catherine
    Myer, Landon
    Waitt, Catriona
    Lamorde, Mohammed
    Kambugu, Andrew
    Reynolds, Helen
    Khoo, Saye
    Taegtmeyer, Miriam
    BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)
  • [4] Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
    Zakumumpa, Henry
    Kiguba, Ronald
    Ndagije, Helen Byomire
    Ategeka, Gilbert
    Ssanyu, Jacquellyn Nambi
    Kitutu, Freddy Eric
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [5] Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
    Henry Zakumumpa
    Ronald Kiguba
    Helen Byomire Ndagije
    Gilbert Ategeka
    Jacquellyn Nambi Ssanyu
    Freddy Eric Kitutu
    BMC Infectious Diseases, 22
  • [6] "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
    Alhassan, Yussif
    Twimukye, Adelline
    Malaba, Thokozile
    Myer, Landon
    Waitt, Catriona
    Lamorde, Mohammed
    Colbers, Angela
    Reynolds, Helen
    Khoo, Saye
    Taegtmeyer, Miriam
    BMC WOMENS HEALTH, 2022, 22 (01)
  • [7] Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study
    Henry Zakumumpa
    Freddy Eric Kitutu
    Helen Byomire Ndagije
    Nakitto-Kesi Diana
    Jacquellyn Nambi Ssanyu
    Ronald Kiguba
    BMC Infectious Diseases, 21
  • [8] Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study
    Zakumumpa, Henry
    Kitutu, Freddy Eric
    Ndagije, Helen Byomire
    Diana, Nakitto-Kesi
    Ssanyu, Jacquellyn Nambi
    Kiguba, Ronald
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [9] Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
    Adelline Twimukye
    Miriam Laker
    Eva Agnes Laker Odongpiny
    Florence Ajok
    Henry Onen
    Ivan Kalule
    Phoebe Kajubi
    Kay Seden
    Noela Owarwo
    Agnes Kiragga
    Mari Armstrong-Hough
    Anne Katahoire
    Andrew Mujugira
    Mohammed Lamorde
    Barbara Castelnuovo
    BMC Infectious Diseases, 21
  • [10] “It’s only fatness, it doesn’t kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
    Yussif Alhassan
    Adelline Twimukye
    Thokozile Malaba
    Landon Myer
    Catriona Waitt
    Mohammed Lamorde
    Angela Colbers
    Helen Reynolds
    Saye Khoo
    Miriam Taegtmeyer
    BMC Women's Health, 22